Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 15/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31408354 | 0.91 | PRKAG1 (0.48) | PTGESSMN1; SMN2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408477 | 0.89 | DGAT1 (0.42) | PTGESSMN1; SMN2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408441 | 0.87 | PTGES (0.49) | PTGESSMN1; SMN2 | |
| SCHEMBL31408311 | 0.87 | SMN1; SMN2 (0.39) | PTGESSMN1; SMN2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408569 | 0.86 | SMN1; SMN2 (0.39) | PTGESSMN1; SMN2MTNR1AMTNR1BACACB | |
| SCHEMBL31408611 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2CNR1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408372 | 0.84 | TDO2 (0.39) | SMN1; SMN2PRKAG1PRKAA1PRKAB1MTNR1A | |
| SCHEMBL31408238 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2CNR1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408586 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2PRKAG1PRKAA1PRKAB1MTNR1A | |
| SCHEMBL31408351 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2PRKAG1PRKAA1PRKAB1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049604-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |